Member Info for LochinvarLass

Today is Wednesday. Typically SPs have been falling on the day, leading some to sell early am, and pick up even more before the close, or so I'm told

Good points. Personally I'd like to know which platform lets you trade at £1.22 - my platform's minimum is around £90.

Link https://pubmed.ncbi.nlm.nih.gov/33725121/

Multinational paper, hope some findnit interesting

If you are issuing a briefing in late Feb and you know it quill happen on March I think most firms would say by the end of Q1.

As it is, Q2 is 11 days away so Top of the Morning to you on the fine St Patrick's Day - I heard a weather warning whilst out yesterday, so should you be waking up to the cold white stuff, I hope you enjoyed the fine warm day we had yesterday

How does your list compare to the schedule in the v-000-xxxx presentation? The schedule for news announcements for near and medium term announcements was published in it.

Nothing expected before end Q1 2021 - all nearest dates were H1 2021 - which means before 30 June (and that was not for the complete product range).

I would be happy if Scancell simply did a single tweet every day, and perhaps engage with their followers or other key industry accounts on things which would strengthen their reputation. Why? Because we have months before any price sensitive advancements can be announced (eg the completion of human trials).

ATB

Knowlesi,

I'm sure I'm classed as part of team ramp. That doesn't mean that I would like to be the share price to be so far above the analyst's view that we stymie interest from those who are currently looking at opportunities where share prices are expected to grow by 30-50% in a shorter period of time.

In terms of the news timelines Cliff, there was nothing before H1 2021. To me that means April at the earlies - otherwise a presentation in Feb/early March would have noted Q1 instead.

I think it is great that Scancell are getting the brand in the press, so that when the news lands, there is a stable of "noteworthy" articles which those new to the arena (and investing) can read - regardless of their political persuasion. Getting this baseline of "important and valuable research" in a way which the average person can understand is a goal worth pursuing as it will help new investors become long term investors rather than speculators.

All the best and as always, nothing I say should be construed as financial advice. Usually if I buy Scancell, the price drops, so I'm going to hold off for a few weeks if I can (smiley face). #DYOR

I am not expecting news until after the first of April. I do think that keeping the name in the press is preventing a fall, but that isn't the same as a change in the current intrinsic value, which I believe still stand at just under 18p.

I would love to think that any delay in news after mid April would be so the analysts can do a thorough review.

ATB All - I'm out and about, so I won't check in again until this evening or tomorrow morning.

I didn't spot any new "news" on their page, though it is dated today. The How it is doing section is out of date in my view given the v-o---x presentation a few weeks ago.

Indeed, I've only seen a few people calling out a 3rd wave. I hope that people take care and ensure that they insist on getting both jabs.

Thank you for posting this. It makes it worth coming to the board.

AIM shares are always high risk investments, so even if Scancell crack the science, there are other factors. That said, whether you are a day trader or in stocks for long term investment strategies, I don't think it hurts to have a punt in a few speculative ventures - providing of course that you can afford to lose all of it.

My family have had a variety of mundane and unusual cancers, which is how I came across Scancell in the first place. I'm very hopeful that cancer vaccines will help millions in the near term, without causing the number of bankruptcies due to medical costs as seen across the USA.

My next questions revolve around how will people spend their healthier, longer lives. I hope that some here will be around long enough to find out.

Efficacy rate is therefore 50-60% - hospitalisations are not the same thing as not getting Covid19 at all. Given the number of long covid complications, I would have thought most people would want full protection.

Did they receive their first but not their 2nd? If so, when will people wake up to the fact that a 40%-50% contagion rate after 1 jab is not effective?

We need to do more to help the most vulnerable.

Thanks Muckled - We have a new addition to the household, so I haven't spent as much time online of late. Like yourself, I was impressed with the calibre of the team. Looking forward to their success

Moon actually I meant t-r-a-d-ing-v-i-e-w -

I particularly like the public consolidation (squeeze) indicator - unfortunately it is 15 minutes behind the market, so it doesn't work very well for Scancell (yet).

Moon, I thought I had replied, but I mentioned the name of another site, so my post may have been removed. If you wouldn't mind, I'd love to hear what you think about LSE's Level 2. ATB, LL

Moon, If you could, let me know how you find LSE's level 2 facility. I've been relying on tradingview thus far. ATB, LL

When you say phase 1, do you mean the CT After the CT for safety?

I would not have expected the human safety trial Cliff spoke of to cost that much.

I believe blod clots have been mentioned in other countries as well. Perhaps why some countries have limited its use to younger age groups.

What is the number who have had both doses in the UK? We don't need and even deadlier variant popping up because of the insistence on continued view that one jab is sufficient. Better to continue lockdown and actually get the most vulnerable both jabs. Local GP has advised that they will notify people when they have any vaccine, and to arrange schedules so that things can be cancelled / rearranged.

Link: https://www.reuters.com/article/us-health-coronavirus-variant-britain/uk-covid-19-variant-has-significantly-higher-death-rate-study-finds-idUSKBN2B213E

Guess that's a "win" for herd immunity without an effective vaccine.

A highly infectious variant of COVID-19 that has spread around the world since it was first discovered in Britain late last year is between 30% and 100% more deadly than previous dominant variants, researchers said on Wednesday.